ライフサイエンスコーパス: ischaemic heart disease

1 n the prevention, diagnosis and treatment of ischaemic heart disease.

2 he treatment of heart failure resulting from ischaemic heart disease.

3 towards resident-cell-based therapy in human ischaemic heart disease.

4 tions for the management of hypertension and ischaemic heart disease.

5 , chronic obstructive pulmonary disease, and ischaemic heart disease.

6 ase (ECSOD) may predispose human carriers to ischaemic heart disease.

7 sed for the treatment of hyperlipidaemia and ischaemic heart disease.

8 ceived nicorandil for symptomatic control of ischaemic heart disease.

9 nfer benefits in models of heart failure and ischaemic heart disease.

10 an lower socioeconomic groups for stroke and ischaemic heart disease.

11 the general population and in patients with ischaemic heart disease.

12 ctions in case fatality rates for stroke and ischaemic heart disease.

13 lly, with nearly half of these deaths due to ischaemic heart disease.

14 and alleviate inflammation in patients with ischaemic heart disease.

15 or translating the findings to patients with ischaemic heart disease.

16 mainly due to a decline in the incidence of ischaemic heart disease.

17 on blood pressure and deaths from stroke and ischaemic heart disease.

18 jor cardiovascular outcomes in patients with ischaemic heart disease.

19 ns is a long-term increase in mortality from ischaemic heart disease.

20 d pharmacological interventions for treating ischaemic heart disease.

21 may represent a viable strategy for treating ischaemic heart disease.

22 role for lipoprotein(a) and triglycerides in ischaemic heart disease.

23 tein(a), and triglycerides for prevention of ischaemic heart disease.

24 atment of cardiovascular disease, especially ischaemic heart disease.

25 effects of air pollution in individuals with ischaemic heart disease.

26 are therefore a novel therapeutic target in ischaemic heart disease.

27 ar disease and two (Hong Kong and Macao) had ischaemic heart disease.

28 patho-vagal transmission in hypertension and ischaemic heart disease.

29 neurons, represents a 'neural signature' of ischaemic heart disease.

30 One patient on placebo died of ischaemic heart disease.

31 Chronic angina is a common manifestation of ischaemic heart disease.

32 treatment groups]), stroke 1.06 (0.83-1.36), ischaemic heart disease 0.76 (0.60-0.95, p=0.02), and en

33 ed mortality from all major causes of death (ischaemic heart disease 0.81 [0.78-0.85], cerebrovascula

34 95-0.928; cardiovascular 0.911, 0.894-0.928; ischaemic heart disease 0.904, 0.882-0.927; cerebrovascu

35 ase subtypes, we observed a 9% lower risk of ischaemic heart disease (0.91, 0.85-0.98), a non-signifi

36 st of the time 0.98, 95% CI 0.94-1.01), from ischaemic heart disease (0.97, 0.87-1.10), or from cance

37 erebrovascular disorders [0.76 (0.74-0.78)], ischaemic heart disease [0.78 (0.76-0.80)], thrombotic d

38 ng 1.12 million deaths (1.07 to 1.16) due to ischaemic heart disease, 0.63 million deaths (0.60 to 0.

39 5 [1.01-1.10]), and linear associations with ischaemic heart disease (1.03 [1.00-1.05]), ischaemic st

40 scular diseases (HR 0.73, 95% CI 0.53-1.01), ischaemic heart disease (1.04, 0.48-2.26), cerebrovascul

41 erebrovascular disease (1.09, 1.04-1.14) and ischaemic heart disease (1.10, 1.09-1.11); and low birth

42 ion in the number of years of life lost from ischaemic heart disease (10-19% in London, 11-25% in Del

43 The biggest contributors were ischaemic heart disease (152 171 excess deaths), respira

44 mong males than females), road injuries, and ischaemic heart disease (1611.8 [1405.0-1856.3]).

45 ounts, the leading level 3 NCDs in 2023 were ischaemic heart disease (193 million [176-209] DALYs), s

46 population [95% CI -8.16 to 0.80]; p=0.107), ischaemic heart disease (-2.21 per 100,000 [-6.86 to 2.4

47 to cardiometabolic conditions, particularly ischaemic heart disease (30%).

48 Most delayed deaths were from ischaemic heart disease (43%) and stroke (33%), with can

49 vourable than those of medical treatment for ischaemic heart disease ($500.41-706.54 per DALY) and HI

50 The leading causes of death in 1990 were ischaemic heart disease (6.3 million deaths), cerebrovas

51 w-and-middle-income countries (1,224,000 for ischaemic heart disease, 623,000 for stroke).

52 /1510) and self-reported physician-diagnosed ischaemic heart disease (686/4006 vs 192/1510) than men

53 chronic obstructive pulmonary disease (60%), ischaemic heart disease (83-89%), and stroke (70-76%).

54 ing cause of death in the region in 2013 was ischaemic heart disease (90.3 deaths per 100 000 people)

55 Given that many factors contribute to ischaemic heart disease, a multifactorial approach to pr

56 ical violence and major depressive disorder, ischaemic heart disease, alcohol use disorder, eating di

57 level 3 causes were lower than expected for ischaemic heart disease, Alzheimer's disease, headache d

58 792,000 (53%) of deaths from ischaemic heart disease and 345,000 (49%) from stroke th

59 assigned to diabetes, 1 490,000 deaths from ischaemic heart disease and 709,000 from stroke were att

60 is the most common clinical manifestation of ischaemic heart disease and a leading cause of mortality

61 cells that could contribute new muscle after ischaemic heart disease and acute myocardial infarction.

62 For ischaemic heart disease and all cardiovascular disease,

63 of comorbidities such as diabetes mellitus, ischaemic heart disease and atrial fibrillation are cruc

64 e use of advanced imaging modalities in both ischaemic heart disease and cardiac amyloidosis.

65 cer, one patient assigned riluzole died from ischaemic heart disease and coronary artery thrombosis,

66 eaths; 10.7% [9.8-11.3] of all deaths) after ischaemic heart disease and COVID-19, and the fourth mos

67 een implicated in causing excess deaths from ischaemic heart disease and exacerbations of COPD.

68 potentially the prevention or resolution of ischaemic heart disease and heart failure.

69 sion, cardiac remodelling, and the resulting ischaemic heart disease and heart failure.

70 in terms of hypertension, diabetes mellitus, ischaemic heart disease and hyperlipidemia.

71 Age-standardised YLL rates for ischaemic heart disease and ischaemic stroke attributabl

72 d children with Kawasaki disease, leading to ischaemic heart disease and myocardial infarction.

73 with the presence of hypertension, diabetes, ischaemic heart disease and peripheral vascular disease

74 e CKB, 489 586 participants without previous ischaemic heart disease and stroke at recruitment were i

75 Ischaemic heart disease and stroke collectively killed 1

76 cardiovascular risk factors and with risk of ischaemic heart disease and stroke in adult life.

77 Relative risks for ischaemic heart disease and stroke mortality were from a

78 While ischaemic heart disease and stroke persist as leading ca

79 ntrations of blood glucose on mortality from ischaemic heart disease and stroke worldwide.

80 nd diarrhoea decreased by 45-54% since 1990; ischaemic heart disease and stroke YLLs increased by 17-

81 to those typical across the time series (ie, ischaemic heart disease and stroke).

82 tients aged 18 years or older with suspected ischaemic heart disease and with at least 50% stenosis i

83 able coronary artery disease' (CAD), 'stable ischaemic heart disease', and 'chronic coronary syndrome

84 reased annually by 3.6% for stroke, 5.4% for ischaemic heart disease, and 4.2% for any cause, between

85 y rates, and mean length of stay for stroke, ischaemic heart disease, and any cause in all relevant i

86 decreased by around 2% annually for stroke, ischaemic heart disease, and any cause, but decreased to

87 o all causes, and to cardiovascular disease, ischaemic heart disease, and cancer in 19 496 men and wo

88 y due to all causes, cardiovascular disease, ischaemic heart disease, and cancer.

89 ty before Jan 1, 2012, from all causes, from ischaemic heart disease, and from cancer in women who di

90 iabetes mellitus, hypothyroidism, history of ischaemic heart disease, and history of tuberculosis wer

91 ditions such as hypertension, heart failure, ischaemic heart disease, and nephropathy.

92 cular disease as the leading cause, five had ischaemic heart disease, and one had lung cancer (Hong K

93 tients with dilated cardiomyopathy, ten with ischaemic heart disease, and six with dilated cardiomyop

94 ratios for acute coronary syndrome, chronic ischaemic heart disease, and stroke were 0.70 (0.69 to 0

95 In 2013, the leading cause of YLLs was ischaemic heart disease, and the leading cause of DALYs

96 nary effects of walking in people with COPD, ischaemic heart disease, and those free from chronic car

97 and their application to treat patients with ischaemic heart disease are challenges that lie ahead.

98 Gy), with the next largest contribution from ischaemic heart disease (around 0.30-1.20% per Gy).

99 y bypass surgery), angina and/or unspecified ischaemic heart disease as a cause of death; additional

100 GP consultation rates were also reduced for ischaemic heart disease, asthma, and gastro-oesophageal

101 ry of stroke, transient ischaemic attack, or ischaemic heart disease at baseline.

102 gastrointestinal bleeding, and patients with ischaemic heart disease at baseline.

103 al admissions (74 313 for stroke, 69 446 for ischaemic heart disease) between 2009 and 2016.

104 rial in patients aged 60 years or older with ischaemic heart disease but no history of gout, there wa

105 e patients were aged 60 years or older, with ischaemic heart disease but no history of gout.

106 ad higher case fatality rates for stroke and ischaemic heart disease, but greater reductions in case

107 have higher future risks of hypertension and ischaemic heart disease, but long-term risks of heart fa

108 age-adjusted and sex-adjusted mortality for ischaemic heart disease, cancer, and a composite of all

109 Cardiovascular diseases (CVDs), such as ischaemic heart disease, cardiomyopathy, atherosclerosis

110 6 months to compare incident cardiovascular (ischaemic heart disease, cerebral infarction, heart fail

111 he prevalences of type 2 diabetes, dementia, ischaemic heart disease, cerebrovascular disease, and ca

112 e (2.83 [1.29-6.17]), but not with diabetes, ischaemic heart disease, cerebrovascular disease, chroni

113 stimated the relative risk of mortality from ischaemic heart disease, cerebrovascular disease, chroni

114 inatal disorders, unipolar major depression, ischaemic heart disease, cerebrovascular disease, tuberc

115 non-breast cancer, cardiovascular diseases, ischaemic heart disease, cerebrovascular diseases, contr

116 leading five causes of DALYs were diabetes, ischaemic heart disease, chronic kidney disease, low bac

117 disease, but significantly greater rates for ischaemic heart disease, chronic obstructive pulmonary d

118 RR 3.78, 2.78-5.14), and ischaemic stroke or ischaemic heart disease (combined RR 2.03, 1.66-2.47).

119 ular events outcome that also included other ischaemic heart disease, coronary revascularisation, and

120 disability adjusted life years (DALYs) were ischaemic heart disease, diabetes, lung cancer, low back

121 of 67 mmol/mol (8.3%), and risk factors for ischaemic heart disease enrolled in the ACCORD trial.

122 rtainty interval 2685-2853), 13 632 incident ischaemic heart disease events (13 153-14 029), 5287 isc

123 Ischaemic heart disease evokes a complex immune response

124 f disability-adjusted life-years (DALYs) was ischaemic heart disease for males and lower respiratory

125 oke and increased by 4.6% (-3.3 to 10.7) for ischaemic heart disease from 1990 to 2017.

126 th high early adulthood adiposity, including ischaemic heart disease, haemorrhagic stroke, and ischae

127 dence of cardiovascular diseases as a group, ischaemic heart disease, haemorrhagic stroke, and ischae

128 Ischaemic heart disease has a multifactorial aetiology a

129 material from patients with DCM (n = 21) or ischaemic heart disease (HD; n = 10) and from normal don

130 iology of cardiovascular diseases, including ischaemic heart disease, heart failure, and arrhythmias.

131 sis, atrial fibrillation or flutter, chronic ischaemic heart disease, heart failure, peripheral arter

132 ociated with a significantly reduced risk of ischaemic heart disease (HR 0.80 [95%CI 0.72-0.87]), cer

133 Ischaemic heart disease, hypertension, diabetes mellitus

134 H) (11.1%), cardiomyopathy (CMP) (7.1%), and ischaemic heart disease (IHD) (6.3%).

135 f alanine aminotransferase (ALT) levels with ischaemic heart disease (IHD) and cardiovascular disease

136 Ischaemic heart disease (IHD) and ischaemic stroke are l

137 associations between HCMV and incident CVD, ischaemic heart disease (IHD) and stroke.

138 ricular systolic dysfunction had evidence of ischaemic heart disease (IHD) from history or ECG criter

139 are small at birth are at increased risk of ischaemic heart disease (IHD) in later life.

140 Ischaemic heart disease (IHD) is the primary cause of ca

141 history of stillbirth had a greater risk of ischaemic heart disease (IHD) RR 1.56, 95% CI [1.30, 1.8

142 cardiovascular diseases (CVD) [CVD and also ischaemic heart disease (IHD), myocardial infarction (MI

143 coexistence of two or three CMDs, including ischaemic heart disease (IHD), stroke, and type 2 diabet

144 ing a growing number of cancer patients with ischaemic heart disease (IHD).

145 ere more than 55,000 vascular deaths (34,000 ischaemic heart disease [IHD], 12,000 stroke, 10,000 oth

146 uring follow-up (myocardial infarction [MI], ischaemic heart disease [IHD], cardiomyopathy, and heart

147 an proteins to conventional risk factors for ischaemic heart disease improved C-statistics from 0.845

148 causes, and from cardiovascular disease, and ischaemic heart disease in men and women.

149 oncentration is a modifiable risk factor for ischaemic heart disease in middle-aged people with type

150 mia could substantially increase the risk of ischaemic heart disease in patients with type 2 diabetes

151 nd 1992 and on recall of physician-diagnosed ischaemic heart disease in the 1992 questionnaire.

152 tives had some adverse effect on deaths from ischaemic heart disease in women who smoked 15 or more c

153 th at least one factor suggesting underlying ischaemic heart disease, including previous myocardial i

154 les with increased myocardial infarction and ischaemic heart disease, independent of the standard, es

155 , cancer (solid tumour IRR 0.75, 0.62-0.89), ischaemic heart disease (IRR 0.65, 0.51-0.85), and parti

156 Ischaemic heart disease is a consequence of coronary ath

157 Ischaemic heart disease is the world's leading cause of

158 f selected cardiovascular disease defined as ischaemic heart disease, ischaemic stroke, and heart fai

159 lar disease and its subcategories (including ischaemic heart disease, ischaemic stroke, haemorrhagic

160 th cardiovascular disease (i.e. a history of ischaemic heart disease, ischaemic stroke, heart failure

161 for atherosclerotic cardiovascular disease, ischaemic heart disease, ischaemic stroke, or peripheral

162 ctors have helped to reduce the incidence of ischaemic heart disease, it remains a major cause of dea

163 Ischaemic heart disease limits oxygen and metabolic subs

164 Ischaemic heart disease, lower respiratory infections, s

165 Age-standardised stroke, ischaemic heart disease, lung cancer, chronic obstructiv

166 s from non-communicable diseases--especially ischaemic heart disease, mental disorders such as depres

167 246; 95% CI 0.036, 0.469; p = 0.021) and for ischaemic heart disease (n = 6410; excess relative risk/

168 troke (n=3285; 1.18 [1.12-1.24]) rather than ischaemic heart disease (n=2363; 1.06 [0.99-1.14]).

169 ors in identification of cause of death were ischaemic heart disease (n=27), pulmonary embolism (11),

170 patients with multivessel disease and stable ischaemic heart disease, non-ST-segment elevation acute

171 often described as Alzheimer's disease) and ischaemic heart disease, obesity, hypertension, hyperlip

172 A quarter of patients had ischaemic heart disease, of which two-thirds had no prev

173 to-vigorous-intensity PA) with incident CVD (ischaemic heart disease or cerebrovascular disease), adj

174 Individuals with ischaemic heart disease or COPD were recruited from exis

175 oint of major cardiovascular events (stroke, ischaemic heart disease or heart failure) according to A

176 n; history of cancer, renal disease, stroke, ischaemic heart disease or respiratory disease; statin u

177 nd older with angiographically proven stable ischaemic heart disease or stage 2 Global initiative for

178 d metabolism (OR 1.22, 95% CI 1.12-1.34) and ischaemic heart disease (OR 1.30, 95% CI 1.15-1.47).

179 We found that patients with aortic stenosis, ischaemic heart disease, or cardiomyopathy had higher ci

180 ur major subtypes of cardiovascular disease (ischaemic heart disease, other heart disease, cerebrovas

181 for all circulatory disease (p = 0.014) and ischaemic heart disease (p = 0.003), possibly due to com

182 t DALYs were mostly those causing mortality (ischaemic heart disease, perinatal conditions, chronic r

183 eneous in patients with heart failure due to ischaemic heart disease, possibly indicating variations

184 quality of medical education with a focus on ischaemic heart disease prevention for physicians, nurse

185 osclerosis and its clinical manifestation as ischaemic heart disease remains a considerable health bu

186 echanisms and in the quality of health care, ischaemic heart disease remains the leading cause of dea

187 Ischaemic heart disease represents the leading cause of

188 nd 154 proteins were associated with risk of ischaemic heart disease, respectively.

189 rom the prospective, population-based Kuopio Ischaemic Heart Disease Risk Factor Study who were aged

190 of the prospective, population-based Kuopio Ischaemic Heart Disease Risk Factor Study, were included

191 70 women examined in 1998-2001 in the Kuopio Ischaemic Heart Disease Risk Factor Study.

192 in the prospective, population-based Kuopio Ischaemic Heart Disease Risk Factor Study.

193 in the prospective, population-based Kuopio Ischaemic Heart Disease Risk Factor Study.

194 s of the prospective population-based Kuopio Ischaemic Heart Disease Risk Factor Study.

195 rly in life has some persisting influence on ischaemic heart disease risk in adult life.

196 All circulatory-disease and ischaemic-heart-disease risk reduces with increasing tim

197 rction and self-reported physician-diagnosed ischaemic heart disease seen in men whose father's socia

198 hearts of 19 patients with end-stage CHF (12 ischaemic heart disease, seven dilated cardiomyopathy),

199 Ischaemic heart disease, stroke, cardiomyopathy and myoc

200 In 2019, leading causes of death were ischaemic heart disease, stroke, chronic obstructive pul

201 common non-communicable diseases, including ischaemic heart disease, stroke, chronic obstructive pul

202 Ischaemic heart disease, stroke, chronic obstructive pul

203 s one of the most important risk factors for ischaemic heart disease, stroke, other cardiovascular di

204 idence of myocardial infarction, other acute ischaemic heart disease, stroke, pulmonary embolism and

205 t cancer, colorectal cancer, depression, and ischaemic heart disease--that are associated with physic

206 ons for miscoding of important diseases (eg, ischaemic heart disease) to estimate worldwide and regio

207 ients were those aged 18 years or older with ischaemic heart disease undergoing planned stent implant

208 e baseline model were (in descending order): ischaemic heart disease, unipolar major depression, road

209 class on non-fatal myocardial infarction and ischaemic heart disease was only seen in men whose adult

210 The standardized mortality ratio for ischaemic heart disease was significantly elevated for t

211 (6.0%), and in female indivduals (6.1%), but ischaemic heart disease was the leading cause of DALYs i

212 Ischaemic heart disease was the leading cause of DALYs w

213 Overall, ischaemic heart disease was the main reported cause of h

214 Ischaemic heart disease was the top cause of death in th

215 DALY rates for ischaemic heart disease were greater in urban areas.

216 deaths attributable to this risk factor from ischaemic heart disease were in low-and-middle-income co

217 Comorbidities such as ischaemic heart disease were obtained from their medical

218 teers, 40 individuals with COPD, and 39 with ischaemic heart disease were recruited.

219 Stroke and ischaemic heart disease were the leading causes of death

220 termine basal CRP levels has implications in ischaemic heart disease, where CRP level is an important

221 old woman with advanced heart failure due to ischaemic heart disease who underwent an upgrade from VV

222 lcoholic liver disease will shortly overtake ischaemic heart disease with regard to years of working

223 interact and contribute to the occurrence of ischaemic heart disease, with a particular attention on

224 ars, with chronic or acute coronary syndrome ischaemic heart disease, with an indication for PCI, wit